Do Not Increase Trazodone to 100 mg for Insomnia
The American Academy of Sleep Medicine (2017) explicitly recommends against using trazodone for insomnia treatment, and you should discontinue it rather than increase the dose. 1111111 The guideline states that clinicians should NOT use trazodone as a treatment for sleep onset or sleep maintenance insomnia versus no treatment in adults, based on moderate-quality evidence showing harms approximately equal to or outweighing benefits.
Why Trazodone Should Not Be Used
The 2017 AASM guideline carries a weak recommendation AGAINST trazodone based on:
- Low-quality evidence for efficacy at 50 mg doses
- Harms approximately equal to benefits 11
- Limited evidence base with very short study durations (mean 1.7 weeks) 2
The 2019 VA/DoD guidelines similarly advise against trazodone for chronic insomnia, noting that while it improved subjective sleep quality, there were no differences in objective measures like sleep onset latency, total sleep time, or wake after sleep onset 2.
Safety Concerns at Higher Doses
While you're asking about 100 mg, the FDA label and clinical evidence reveal significant dose-dependent risks 3:
Serious adverse effects include:
- Priapism (12% incidence reported in one PTSD study—much higher than expected) 4
- Orthostatic hypotension and syncope 3
- Cardiac arrhythmias (QT prolongation risk, especially with CYP3A4 inhibitors) 33
- Serotonin syndrome when combined with other serotonergic drugs 3
- Increased bleeding risk with anticoagulants/antiplatelets 3
Common adverse effects (dose-dependent):
- Somnolence, sedation, dizziness
- Blurred vision
- Cognitive and motor impairment 3
What You Should Do Instead
Switch to an evidence-based medication recommended by the AASM 11:
First-line options (all have WEAK recommendations FOR use):
- Zolpidem 10 mg for sleep onset and maintenance insomnia
- Eszopiclone 2-3 mg for sleep onset and maintenance insomnia
- Temazepam 15 mg for sleep onset and maintenance insomnia
- Zaleplon 10 mg for sleep onset insomnia only
- Suvorexant 10-20 mg for sleep maintenance insomnia
- Doxepin 3-6 mg for sleep maintenance insomnia
- Ramelteon 8 mg for sleep onset insomnia
Clinical Algorithm:
- Discontinue trazodone (taper if used >2 weeks to avoid discontinuation syndrome) 3
- Assess insomnia pattern:
- Sleep onset only → Consider zaleplon, zolpidem, ramelteon, or triazolam
- Sleep maintenance only → Consider doxepin or suvorexant
- Both onset and maintenance → Consider eszopiclone, zolpidem, or temazepam
- Screen for contraindications:
- Sleep apnea or respiratory disease → Avoid benzodiazepines; consider ramelteon or low-dose doxepin
- Elderly patient → Use lower doses; consider doxepin 3 mg or ramelteon
- History of substance use → Consider ramelteon or suvorexant (non-controlled)
Important Caveats
If the patient has comorbid depression requiring antidepressant treatment, trazodone at antidepressant doses (150-400 mg) may be appropriate for the depression itself, with insomnia improvement as a secondary benefit 56. However, low-dose trazodone (50-100 mg) does NOT constitute adequate treatment for major depression 5.
The evidence for trazodone at 100 mg specifically comes primarily from older studies in depressed populations 78, not primary insomnia. One Japanese study found 100 mg improved sleep in patients with depression and insomnia 7, but this doesn't apply to primary insomnia treatment.
Recent meta-analyses 910 show trazodone improves sleep quality and objective total sleep time but is associated with significantly more adverse effects (RR 1.18-4.31 for various adverse events) and more dropouts due to side effects (RR 2.30) 10.
Bottom line: Increasing to 100 mg exposes the patient to greater dose-dependent risks without strong evidence of benefit for primary insomnia. Switch to an AASM-recommended agent instead.